Moleculin Biotech Inc (MBRX)
2.90
+0.07
(+2.47%)
USD |
NASDAQ |
Nov 22, 16:00
2.90
0.00 (0.00%)
After-Hours: 19:56
Moleculin Biotech Total Liabilities (Quarterly): 15.92M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 15.92M |
June 30, 2024 | 7.87M |
March 31, 2024 | 9.258M |
December 31, 2023 | 12.14M |
September 30, 2023 | 4.385M |
June 30, 2023 | 6.847M |
March 31, 2023 | 5.378M |
December 31, 2022 | 5.231M |
September 30, 2022 | 6.955M |
June 30, 2022 | 6.896M |
March 31, 2022 | 6.136M |
December 31, 2021 | 5.097M |
September 30, 2021 | 7.443M |
June 30, 2021 | 8.834M |
March 31, 2021 | 11.27M |
December 31, 2020 | 11.27M |
September 30, 2020 | 12.68M |
June 30, 2020 | 15.75M |
Date | Value |
---|---|
March 31, 2020 | 10.18M |
December 31, 2019 | 9.664M |
September 30, 2019 | 11.42M |
June 30, 2019 | 9.762M |
March 31, 2019 | 6.616M |
December 31, 2018 | 5.313M |
September 30, 2018 | 5.931M |
June 30, 2018 | 7.318M |
March 31, 2018 | 4.359M |
December 31, 2017 | 2.365M |
September 30, 2017 | 1.982M |
June 30, 2017 | 1.98M |
March 31, 2017 | 4.175M |
December 31, 2016 | 1.433M |
September 30, 2016 | 1.330M |
June 30, 2016 | 2.003M |
March 31, 2016 | 0.978M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.385M
Minimum
Sep 2023
15.92M
Maximum
Sep 2024
8.96M
Average
8.352M
Median
Total Liabilities (Quarterly) Benchmarks
Agilent Technologies Inc | 5.093B |
Seelos Therapeutics Inc | 30.51M |
Cara Therapeutics Inc | 50.62M |
Citius Pharmaceuticals Inc | 10.81M |
NovaBay Pharmaceuticals Inc | 2.805M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 23.39M |
Shareholders Equity (Quarterly) | 7.479M |